Nuvilex Inc. (NASDAQ:PMCB) Sees Large Decline in Short Interest

Nuvilex Inc. (NASDAQ:PMCB) saw a large decrease in short interest in the month of December. As of December 31st, there was short interest totaling 62,893 shares, a decrease of 90.1% from the December 15th total of 635,629 shares. Approximately 0.7% of the shares of the stock are sold short. Based on an average daily volume of 447,653 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily volume of 447,653 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.7% of the shares of the stock are sold short.

Nuvilex Stock Down 4.3%

NASDAQ:PMCB traded down $0.04 on Tuesday, hitting $0.86. The stock had a trading volume of 144,799 shares, compared to its average volume of 473,473. The company has a fifty day moving average price of $0.84 and a two-hundred day moving average price of $0.94. Nuvilex has a 1-year low of $0.63 and a 1-year high of $1.90. The stock has a market cap of $8.70 million, a price-to-earnings ratio of -0.64 and a beta of 0.04.

Nuvilex (NASDAQ:PMCB) last released its quarterly earnings results on Thursday, December 18th. The company reported ($0.32) EPS for the quarter.

Insider Transactions at Nuvilex

In related news, CEO Joshua Silverman acquired 40,000 shares of Nuvilex stock in a transaction on Wednesday, January 7th. The stock was bought at an average cost of $0.83 per share, for a total transaction of $33,200.00. Following the completion of the transaction, the chief executive officer owned 416,250 shares of the company’s stock, valued at approximately $345,487.50. The trade was a 10.63% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders purchased a total of 110,000 shares of company stock worth $89,000 in the last quarter. Corporate insiders own 10.33% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Nuvilex in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.